As pharmaceutical patents near their expiration dates, a window of opportunity emerges for companies to explore untapped markets. With the expiration of patents comes the potential for generic versions to flood the market, offering more affordable alternatives to brand-name medications. This shift not only expands access to essential drugs for patients but also presents a fertile landscape for pharmaceutical companies to explore.
By strategically identifying drugs nearing patent expiration, companies can position themselves to capitalize on the resulting opportunities. Through innovative formulations, international expansion, and strategic marketing, pharmaceutical companies can extend their reach to new patient populations and geographic regions. Moreover, leveraging data analytics and partnerships can facilitate targeted approaches, ensuring maximum impact in these emerging markets.
As the pharmaceutical landscape evolves, navigating the transition of drugs from branded to generic status presents a pivotal moment for industry players. By seizing the moment and strategically aligning their efforts, pharmaceutical companies can unlock new avenues for growth, improve patient access, and drive innovation in healthcare delivery worldwide.”
Currently under investigation are the following drugs: One information model we support is a digital asset for a clinical article, view the metadata model.
| Drug | Alternate Names | Manufacturer | Patents Expiration |
|---|---|---|---|
| omontys | Affymax Inc. | May 12, 2024 | |
| aliqopa | Bayer | May 13, 2024 | |
| mayzent | Novartis | May 19, 2024 | |
| prevymis | Merck & Co | May 22, 2024 | |
| xifaxan | Salix Pharmaceuticals | June 19, 2024 | |
| remodulin | orenitram, tyvaso | United Therapeutics | May 24, 2024 |
| tpoxx | SIGA Technologies | June 18, 2024 | |
| nuvigil | Teva Pharmaceuticals | June 18, 2024 | |
| oriahnn | AbbVie Inc. | July 6, 2024 | |
| xeglyze | Dr. Reddy’s Laboratories | July 16, 2024 | |
| ninlaro | Takeda | August 12, 2024 | |
| prezista | Janssen Therapeutics | August 16, 2024 | |
| xarelto | Janssen Therapeutics | August 28, 2024 | |
| moviprep | Velinor A.G | September 1, 2024 | |
| aldara | 3M Pharmaceutical | October 1, 2024 | |
| brilinta | AstraZeneca | October 30, 2024 | |
| xiidra | Novartis | November 5, 2024 | |
| nourianz | Kyowa Kirin Co. | November 13, 2024 |